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of Nesiritide in Patients With Heart Failure
Using Intravascular Doppler and
Quantitative Angiography
Uri Elkayam, MD, FACC, Mohamed W. Akhter, MD, Ming Liu, MD,
Parta Hatamizadeh, MD, Mohamad N. Barakat, MD
Los Angeles, California
O B J E C T I V E S We evaluated the magnitude and site of action of the nesiritide mediated renal
vasodilatory effect in patients with heart failure (HF).
B A C KG ROUND Nesiritide, a recombinant human B-type natriuretic peptide is approved for the
treatment of acute decompensated HF and has been shown to exert favorable hemodynamic, neurohor-
monal, and symptomatic effects. The renal effect of nesiritide in HF patients has not been well deﬁned.
METHOD S In 15 patients with acute decompensated HF, intravascular Doppler and quantitative
angiography of the renal artery were used to assess the effect of nesiritide on renal artery diameter and
velocity time integral as well as renal blood ﬂow and vascular resistance. Nesiritide was administered
intravenously at a standard dose of 2 g/kg bolus followed by a continuous infusion at a rate of 0.01
g/kg/min. Assessment of nesiritide effect was made at 15 min.
R E S U L T S Nesiritide infusion was associated with a signiﬁcant central hemodynamic effect including
a fall in mean pulmonary artery pressure (36  12 mm Hg to 31  13 mm Hg, p  0.001), mean
pulmonary capillary wedge pressure (21  2 mm Hg to 15  10 mm Hg, p  0.001), and systemic
vascular resistance (1,995  532 dynes·s·cm5 to 1,563  504 dynes·s·cm5, r  0.001), and an increase
in cardiac output from 3.9  1.2 l/min to 4.6  1.6 l/min (p  0.001). Nesiritide was also associated with
a signiﬁcant vasodilatory effect on the large conductance renal arteries resulting in an increase in renal
artery diameter from 6.2  0.7 mm to 6.7  0.8 mm (p  0.001). At the same time, there was a
concomitant fall in mean renal artery pressure (99 17 mm Hg to 89 13 mm Hg, p 0.002) and renal
blood ﬂow velocity time integral (27  15 cm/beat to 23  15 cm/beat, p  0.008) and, therefore, no
signiﬁcant change in renal blood ﬂow or renal vascular resistance.
CONC L U S I O N S The nesiritide effect on the renal circulation in patients with HF is complex, with
a marked vasodilatory action on the large, conductance renal arteries but a concomitant fall in velocity
time integral and no effect on renal vascular resistance or renal blood ﬂow. Lack of increase in renal
blood ﬂow may be due to a fall in renal blood pressure or an intrarenal vasoconstrictive effect. (J Am
Coll Cardiol Img 2008;1:765–71) © 2008 by the American College of Cardiology Foundation
From the Division of Cardiology, Department of Medicine, University of Southern California, Keck School of Medicine, Los
Angeles, California. The study was supported by a research grant from SCIOS (Fremont, California). Dr. Elkayam has served
as a consultant and speaker for SCIOS.Manuscript received May 16, 2008; revised manuscript received July 10, 2008, accepted July 21, 2008.
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766enal insufficiency is common in patients hos-
pitalized for heart failure (HF) (1) and has a
significant effect on the ability to correct
volume overload with diuretics (2) and on
hort- and long-term outcome (3). Further wors-
ning of renal function during the hospitalization
esults in prolongation of length of stay as well as
ncreased morbidity and mortality (4). For these
easons, improvement of renal function or at least
revention of its deterioration is an important
herapeutic goal in patients with acute decompen-
ated heart failure (ADHF). Nesiritide, a recombi-
ant human B-type natriuretic peptide (BNP), has
een approved for the treatment of ADHF and has
een shown to have favorable hemodynamic, neu-
ohormonal and symptomatic effects in patients
ith ADHF (2,5). The effect of nesiritide on renal
unction, however, has not been fully understood,
nd available information is conflicting, with some
studies demonstrating improvement (6)
while others suggesting either no effect (7)
or even deterioration (8). More mechanis-
tic information is, therefore, needed in
order to better understand the renal circu-
latory effects of nesiritide in patients with
HF. The use of renal intravascular Dopp-
ler technique and quantitative angiography
of the renal artery allows a direct measure-
ment of changes in renal artery dimensions
as well as in renal artery blood flow velocity
(9) and provides an accurate assessment of
the magnitude and location of the vasodila-
tory effect as well as changes in renal blood
flow (RBF) (10,11). In this study we have
used these techniques to assess the magni-
ude of the renal vasodilatory effect and the site of
ction of nesiritide in patients with HF.
ETHODS
atient selection. The study included 15 patients
dmitted to the Los Angeles County/University of
outhern California Medical Center for ADHF.
ll patients were clinically stable at the time of the
tudy and underwent diagnostic cardiac catheteriza-
ion for clinical indications after initial treatment.
All patients had left ventricular systolic dysfunc-
ion, documented either by radionuclide ventricu-
ography or by echocardiography. Patients with a
ystolic blood pressure less than 95 mmHg or those
ho required treatment with other intravenous
asoactive medications were excluded. In addition,
ed
nceecause of the risk of contrast nephropathy, patients aith serum creatinine 133 mol/l (1.5 mg/dl)
ere also excluded.
tudy protocol. All patients signed a written con-
ent approved by the institutional research commit-
ee. For safety reasons, oral intake including med-
cations was not allowed the morning of the test. A
alloon-tipped, triple lumen pulmonary artery
Swan-Ganz) catheter was placed into the pulmo-
ary artery and a 6-F guiding catheter was placed in
he proximal portion of the renal artery. After full
eparinization, a 0.014-inch Doppler-tipped Flow-
re (Volcano Therapeutics, Rancho Cordova, Cali-
ornia) was introduced into the guiding catheter
nd the tip positioned in the main renal artery or
ne of its major branches. Catheter position in the
rtery was confirmed with a small amount (1 to 3
l) of contrast. Position of the flow wire was
anipulated to achieve the highest possible flow
elocity, and the wire was then locked to prevent
ny change in its position. Renal artery pressures
ere measured directly with the aid of the guiding
atheter, fluid-filled pressure tubing, and standard
ransducers. RBF was measured by quantitative
enal angiography and intravascular Doppler flow
easurement. The spectral Doppler flow velocity
velocity time integral [VTI]) was continuously
ecorded on a high-quality, super VHS videotape
or subsequent analysis, and average peak flow
elocity was measured based on 15 to 20 beats to
orrect for changes related to respiration (Fig. 1).
enal artery lumen diameter (RAD) was measured
lindly by quantitative angiography (QCA Heart-
ab, Westerly, Rhode Island) approximately 5 mm
istal to the tip of the Flowire (Volcano Therapeu-
ics) (Fig. 2).
After the placement of both catheters, baseline
emodynamic measurements, which included heart
ate, renal arterial blood pressure, right atrial pres-
ure (RAP), pulmonary arterial and pulmonary
apillary wedge pressures, were performed along
ith thermodilution cardiac output. Cardiac index,
ystemic and pulmonary vascular resistances, as well
s mean renal arterial blood pressure (MRBP) were
alculated by standard formulas. In addition, renal
rtery Doppler blood flow velocity was recorded,
nd renal artery angiogram using 2 to 3 ml of
ontrast was performed. Renal artery blood flow
as calculated using the following formula: RBF
ml/min)  heart rate (beats/min)  VTI  ( 
RAD2/4), and renal artery vascular resistance
RVR) was calculated as: 80  (MRBP  RAP)/
BF. Nesiritide (Scios Inc., Fremont, California) atB B R E V I A T I O N S
N D A C R O N YM S
DHF acute decompensat
eart failure
NP B-type natriuretic
eptide
F heart failure
RBPmean renal arterial
lood pressure
AD renal artery diameter
AP right atrial pressure
BF renal blood flow
VR renal vascular resistastandard dose of 2-g/kg intravenous bolus was
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767hen administered via a peripheral intravenous line
ollowed by a continuous infusion at a rate of 0.01
g/kg/min. All of the measurements and calcula-
ions mentioned in the preceding text were repeated
n every patient at 15 min of nesiritide infusion.
ssessment of nesiritide effect was done at 15 min
n order to avoid an excessive prolongation of the
atient procedures. The rest of the diagnostic tests
ncluding left heart catheterization and angiography
ere performed after the completion of the study
rotocol.
ata analysis. Because of the relatively small num-
er of cases and lack of normality of distributions,
he nonparametric Wilcoxon signed rank test was
erformed to compare measured and calculated
Figure 1. Example of Renal Artery Blood Flow Velocity Measure
Renal blood ﬂow velocity as measured with a Doppler Flowire (Volc
Figure 2. Example of a Quantitative Angiography of the Renal ARenal artery diameter (RAD) as obtained by quantitative angiography aarameters between the baseline and at 15 min of
esiritide infusion in all 15 patients. All group
alues were presented as mean  SD. A probability
alue of 0.05 was considered as statistically
ignificant.
E SULTS
eneral information. Of the 15 patients who were
nrolled into the study, there were 4 female subjects
nd 11 male subjects. Mean age was 53  16 years,
anging from 24 to 78 years. The etiology of HF
as coronary artery disease in 6 patients and nonis-
hemic cardiomyopathy in the others. None of the
atients were found to have angiographic evidence
y Intravascular Doppler Technique
Therapeutics) at baseline (A) and during nesiritide infusion (B).
ryd brtet baseline and during nesiritide infusion.
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768f renal artery atherosclerotic disease. Left ventric-
lar ejection fraction ranged from 10% to 38%
mean: 25 9%). Mean serum creatinine was 97
ean Values of RAD and VTI
p values of renal artery diameter (RAD) and velocity time integral
eline (BL) and at 15 min of nesiritide infusion (IN) at a dose of 0.01
after intravenous bolus administration of 2 g/kg. Continuous infu-
iritide was associated with a progressive signiﬁcant dilation of the
0.7 mm to 6.7  0.8 mm, p  0.001), but at the same time a signif-
ments of Systemic and Renal Hemodynamic Parameters at
in After Intravenous Infusion of Nesiritide in 16 Patients With HF
Mean  SD
p ValueBaseline Infusion
79 16 81 16 0.444
135 28 123 22 0.003
79 12 71 10 0.001
99 17 89 13 0.002
9 6 7 5 0.061
55 19 49 22 0.001
26 8 22 9 0.001
36 12 31 13 0.001
21 8 15 10 0.001
3.9 1.2 4.6 1.6 0.001
2.2 0.5 2.5 0.6 0.001
) 1,995 532 1,563 504 0.001
) 315 157 305 157 0.632
27 15 23 15 0.008
6.2 0.7 6.7 0.8 0.001
) 14,568 7,334 13,609 6,654 0.45
623 326 647 412 0.15
 cardiac output; DPA  diastolic pulmonary artery (pressure); DRBP  diastolic
F heart failure; HR heart rate; MPAmean pulmonary artery (pressure); MRBP
ressure; PCWP  pulmonary capillary wedge pressure; PVR  pulmonary vascular
l artery diameter; RAP  right atrial pressure; RBF  renal artery blood ﬂow; RVR
tance; SPA  systolic pulmonary artery (pressure); SRBP  systolic renal blood
ic vascular resistance; VTI  velocity-time integral.c
VTI (27  6 cm to 23  15 cm, p  0.001).8 mol/l (1.1  0.2 mg/dl) and MRBP was 99 
7 mm Hg.
All patients were on oral furosemide and
ngiotensin-converting enzyme inhibitors, 12 pa-
ients were also on digoxin (75%), 10 patients on
eta-blockers (69%), 8 on aspirin (56%), 2 on
pironolactone (12%), and 1 patient on nitrates
6%).
aseline versus 15-min infusion. Results of the anal-
ses between baseline and 15 min of nesiritide
nfusion are shown in Table 1. There were signifi-
ant reductions in renal arterial blood pressures and
ulmonary arterial pressure as well as in pulmonary
apillary wedge pressure and a borderline significant
eduction in RAP (p  0.06). In addition, calcu-
ated value of systemic vascular resistance was also
ecreased, while cardiac output and cardiac index
ere significantly increased. There was no signifi-
ant change in heart rate and pulmonary vascular
esistance. Nesiritide infusion also resulted in a
ignificant increase in RAD, but at the same time,
fall in VTI (Fig. 3). These renal circulatory effects
ere not associated with a significant change in
ither RBF (Fig. 4) or RVR.
I SCUS S ION
uantitative angiography and intravascular Dopp-
er techniques have been extensively used for eval-
ation of coronary anatomy (12) and for the assess-
ent of coronary blood flow reserve (13). These
echniques have also been validated and used for
he measurements of changes in RAD and RBF
9–11,14–16). Our group has used these methods
o gain further insight into the renal circulatory
ffect of various therapeutic interventions in pa-
ients with HF (10,17,18). The use of these tech-
iques in the present study has indicated that
ompared with its systemic effect the renal circula-
ory action of nesiritide is more complex. A bolus
dministration followed by continuous infusion of
he standard recommended dose of the drug was
ssociated with a progressive dilation of the large
onductance renal arteries, but at the same time a
all in VTI and, therefore, no significant change in
BF and only a small and statistically insignificant
all in RVR. The findings of this unique response to
esiritide are similar to the previously described
ffect of natriuretic peptides in animal experimen-
ations and in healthy humans. Burnett et al. (19)
nd Maack et al. (20) examined the effect of
ynthetic atrial natriuretic peptide on the renalFigure 3. M
Mean grou
(VTI) at bas
g/kg/min
sion of nes
RAD (6.2 Table 1. Measure
Baseline and 15 m
Variable
HR (beats/min)
SRBP (mm Hg)
DRBP (mm Hg)
MRBP (mm Hg)
RAP (mm Hg)
SPA (mm Hg)
DPA (mm Hg)
MPA (mm Hg)
PCWP (mm Hg)
CO (l/min)
CI (l/min/m2)
SVR (dynes·s·cm5
PVR (dynes·s·cm5
VTI (cm/beat)
RAD (mm)
RVR (dynes·s·cm5
RBF (ml/min)
CI  cardiac index; CO
renal blood pressure; H
 mean renal blood p
resistance; RAD  rena
 renal vascular resisirculation in anesthetized dogs and reported a
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769ransient increase in RBF, which was followed by a
ecline to or below baseline values with a continu-
us infusion. A number of studies in normal vol-
nteers has shown an increase in glomerular filtra-
ion rate in response to BNP administration; the
ffect on RBF, however, was variable (21–24).
Although the mechanism of lack of increase in
BF despite a significant augmentation in cardiac
utput and a clearly documented nesiritide-
ediated vasodilation of the conductance renal
rteries is not entirely clear, there are a number of
ossible explanations. Since renal blood pressure
howed a significant decline during continuous
esiritide infusion, the decrease in VTI and lack of
mprovement in RBF may be related to this finding.
his possibility is supported by a study by La Villa
t al. (23) who reported a significant increase in
BF during infusion of BNP in healthy volunteers
t a dose that did not affect the systemic blood
ressure. The relation between RBF and renal
erfusion pressure may also be supported by recent
tudies by Riter et al. (25), who demonstrated a
avorable effect on both urine output and renal
unction of a small (one-half of the standard dose),
onhypotensive dose of nesiritide in patients with
ecompensated HF. Low-dose nesiritide was also
eported to have a favorable effect on renal function
n 2 recent studies evaluating the effect of the drug
n patients undergoing cardiopulmonary bypass sur-
ery. Chen et al. (26) demonstrated prevention of
Figure 4. Effect of Nesiritide on RBF
Individual values of renal blood ﬂow (RBF) in ml/min at baseline (o
studied. Mean values were 631  336 ml/min at baseline and 647ctivation of aldosterone as well as worsening of eenal function observed in patients receiving pla-
ebo with an infusion of a low-dose nesiritide in a
roup of patients undergoing cardiopulmonary by-
ass surgery. Similarly, Mentzer et al. (6) demon-
trated a nesiritide-mediated renal protective effect
ith prevention of worsening renal function and
ugmentation of urine output in patients with HF
ndergoing cardiac surgery. The patients in the
ater study received continuous infusion of nesiritide
t the standard dose but without the initial bolus,
hich was associated with no significant reduction
n systemic blood pressure compared with that in
lacebo. The results of these studies suggest the
eed for further investigation of the potential ben-
fits of a smaller, nonhypotensive dose of nesiritide.
An additional potential explanation for the lack
f significant changes in both RBF and RVR seen
n our study may also be an alteration of intrarenal
asoregulation. Natriuretic peptide-mediated con-
triction of the efferent arterioles concomitant to
ilation of the afferent renal arterioles have been
ell documented in animal experimentations (27–
0). A slower time course of atrial natriuretic
eptide-induced vasoconstriction of efferent arte-
ioles, compared with a prompt vasodilatory re-
ponse of the afferent arterioles in pre-constricted
reparations, has been reported by Camargo et al.
30) in isolated, perfused rat kidneys and has been
uggested to be the result of a secondary release of
e) and at 15 min of nesiritide infusion (brown) in the 15 patients
2 ml/min during the infusion (p  0.15).rangndothelin (31,32).
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770The circulatory effect of nesiritide as demon-
trated in the present study may not be unique to
he renal circulation. Michaels et al. (33) who
xamined the effect of intravenous nesiritide admin-
stration on human coronary arteries also showed a
ifferential vasodilatory effect on the conductance
nd resistance arteries. While the epicardial con-
uctance coronary arteries showed a gradual di-
ation that maximized at 15 min of infusion, the
verage peak blood flow velocity, which is af-
ected mostly by dilation of the resistance vessels,
emonstrated a significant decrease with contin-
ed infusion.
tudy limitations. It should be noticed that the
ethod used in this study for the evaluation of renal
rtery blood flow is likely to represent an underes-
imation of total RBF and is, therefore, not suitable
or accurate measurement of this parameter or RVR
ut rather for assessment of their relative changes.
easons for underestimation include the need to
osition the Doppler wire in a secondary renal
rtery is some patients due to the presence of a short
enal artery with early bifurcation or double main
enal arteries. Additionally, the underestimation
ay result from an inability to divert the wire to the
entral portion of the flow in order to record the
aximum flow velocity especially in a large vessel
uch as the renal artery (Fig. 2) (34). In spite of
hese limitations, this method has been shown to
ccurately assess changes in flow, which are likely to
e proportional to changes in total RBF (10,11,
4,17,18). An additional limitation is related to theheart failure. Classification and re- al. Nesiritide doesatients as part of diagnostic cardiac catheterization
nd that the effect of contrast used for renal artery
ngiography on the vascular effect of nesiritide is
ot known; for these reasons the results of this
tudy may not be completely applicable to symp-
omatic patients with ADHF who are treated with
esiritide early after admission.
ONCLUS IONS
he results of our study suggest a complex effect of
ntravenous nesiritide on the renal circulation in
atients with HF. The drug had a substantial
asodilatory effect on the large, conductance renal
rteries but not on the small resistant vessels. As a
esult of these effects, continuous nesiritide infusion
as not associated with a significant impact on
ither RVR or RBF. Lack of increase in RBF in
pite of a significant increase in cardiac output and
AD may be related to a fall in renal blood pressure
ue to the systemic effect of the drug and to a
elayed vasoconstrictive response of the intrarenal
fferent renal arterioles.
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